Ugrás a tartalomra
Merck
Összes fotó(1)

Fontos dokumentumok

View All Documentation

Y0001182

Captopril for system suitability

European Pharmacopoeia (EP) Reference Standard

Szinonimák:

Captopril, N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(1)

About This Item

Tapasztalati képlet (Hill-képlet):
C9H15NO3S
CAS-szám:
62571-86-2
Molekulatömeg:
217.29
Beilstein:
477887
MDL-szám:
MFCD00168073
UNSPSC kód:
41116107
PubChem Substance ID:
329831295
NACRES:
NA.24

grade

pharmaceutical primary standard

API-család

captopril

gyártó/kereskedő neve

EDQM

mp

104-108 °C (lit.)

alkalmazás(ok)

pharmaceutical (small molecule)

format

neat

tárolási hőmérséklet

2-8°C

SMILES string

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

InChI

1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1

Nemzetközi kémiai azonosító kulcs

FAKRSMQSSFJEIM-RQJHMYQMSA-N

Géninformáció

human ... ACE(1636)

Looking for similar products? Látogasson el ide Útmutató a termékösszehasonlításhoz

Általános leírás

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Alkalmazás

Captopril for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biokémiai/fiziológiai hatások

Angiotensin converting enzyme inhibitor. Inhibits the formation of angiotensin II, a bioactive peptide that stimulates angiogenesis and increases microvessel density.

Kiszerelés

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Egyéb megjegyzések

Sales restrictions may apply.

kapcsolódó termék

Product No.
Leírás
Árazás

1091200

Captopril, United States Pharmacopeia (USP) Reference Standard

1091221

Captopril disulfide, United States Pharmacopeia (USP) Reference Standard

PHR1307

Captopril, Pharmaceutical Secondary Standard; Certified Reference Material

C0430000

Captopril, European Pharmacopoeia (EP) Reference Standard

Y0000435

Captopril impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001221

Captopril impurity D, European Pharmacopoeia (EP) Reference Standard

Y0001219

Captopril impurity B, European Pharmacopoeia (EP) Reference Standard

Y0001220

Captopril impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001450

Captopril impurity J, European Pharmacopoeia (EP) Reference Standard

BP538

Captopril, British Pharmacopoeia (BP) Reference Standard

BP500

Captopril disulfide, British Pharmacopoeia (BP) Reference Standard

Piktogramok

Health hazard
GHS08

Figyelmeztetés

Danger

Figyelmeztető mondatok

H341,H360F

Óvintézkedésre vonatkozó mondatok

P201 - P308 + P313

Veszélyességi osztályok

Muta. 2 - Repr. 1B

Tárolási osztály kódja

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable

Válasszon a legfrissebb verziók közül:

Analitikai tanúsítványok (COA)

Lot/Batch Number

Sajnos jelenleg COA nem áll rendelkezésre ehhez a termékhez online.

Ha segítségre van szüksége, lépjen velünk kapcsolatba Vevőszolgálat

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

R I Ogilvie et al.
The Canadian journal of cardiology, 14(8), 1025-1033 (1998-09-17)
Twenty-four splenectomized dogs were subjected to rapid right ventricular pacing (RRVP) at 250 beats/min for five weeks. During the final three weeks, four groups six dogs were untreated or treated with captopril alone, with the angiotensin II type 1 (AT1)
A O Nur et al.
International journal of pharmaceutics, 194(2), 139-146 (2000-02-29)
The development of oral sustained or controlled release dosage form of captopril has been an interested topic of research for a long period of time. Difficulties encountered with such topic based on the fact that the drug is freely water
Antonio C M Camargo et al.
Toxicon : official journal of the International Society on Toxinology, 59(4), 516-523 (2011-08-13)
The identification of novel endogenous and exogenous molecules acting in the complex mechanism of regulating the vascular tonus has always been of great interest. The discovery of bradykinin (1949) and the bradykinin-potentiating peptides (1965) had a pivotal influence in the
Johannes J Kovarik et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 30(1), 115-123 (2014-08-12)
Blockade of the renin-angiotensin system (RAS) exerts beneficial effects in patients with mild-to-moderate chronic kidney disease, yet evidence suggesting a similar benefit in haemodialysis (HD) patients is not available. Furthermore, knowledge of the effects of RAS blockade on systemic RAS
Samir Attoub et al.
Annals of the New York Academy of Sciences, 1138, 65-72 (2008-10-08)
Lung cancer is the most common form of cancer in the world, and 90% of patients die from their disease. The angiotensin converting enzyme (ACE) inhibitors are used widely as antihypertensive agents, and it has been suggested that they decrease
View All Related Papers

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással